Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Key Highlights
- ➤Cash $403.8 million, expected to fund operations into 2029
- ➤GlyphAllo driving trial showed no next-morning impairment versus placebo
- ➤BUOY-1 MDD enrollment on track; topline data expected 1H 2027
- ➤GlyphAgo Phase 2/3 GAD trial planned to begin in 1H 2027
- ➤Q3 net loss $26.4 million, versus $22.5 million year-earlier
Expert Statements
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Over the last few months, Seaport met two key clinical milestones – we dosed the first patient in the Phase 2a proof-of-pharmacology trial of GlyphAgo in patients with GAD and sleep disturbance, and demonstrated that GlyphAllo did not impair next-morning driving performance in a Phase 1 driving trial”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“With GlyphAllo and GlyphAgo, Seaport is now advancing two Phase 2 programs, and we look forward to progressing these programs through a steady cadence of potential value-creating milestones.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“In this context, our team remains focused on the rigorous execution of the ongoing, potentially registration-enabling Phase 2b BUOY-1 trial of GlyphAllo in MDD.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Enrollment in BUOY-1 is on track, with topline data expected in the first half of next year.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“As we approach the topline readout of BUOY-1, we also continue to explore potential indication expansion opportunities for the GlyphAllo program, including in generalized anxiety disorder.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“In parallel, we are preparing to initiate the Phase 2/3, potentially registration-enabling trial of GlyphAgo in GAD in the first half of next year, and we expect topline data from both Phase 2 trials of GlyphAgo in 2028 – with data from the Phase 2a trial expected in early 2028, and data from the Phase 2/3 trial expected by year-end 2028.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“Seaport is well-capitalized, with cash runway through all three of our upcoming mid-to-late-stage clinical data readouts.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“There are a billion people living with mental illness – waiting and hoping for better medicines.”
Daphne Zohar, Co-Founder and Chief Executive Officer at Seaport Therapeutics
“We are committed to our mission to bring better days to patients and their families.”
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Announced positive topline data from Phase 1 driving simulation trial of GlyphAllo™, showing that GlyphAllo did not impair next-morning driving performance compared to placebo
Get started
Create a free account to read the full story.